Abstract

The heart’s natural provision of pulsatile blood flow has been regarded as an essential requirement for normal organ function, especially critical organs such as the kidney, liver, and brain. However, in this issue of Circulation , Russell and colleagues1 have demonstrated that this tenet of medicine is no longer accurate. Their study examined the long-term impact of nonpulsatile blood flow as provided by a new generation of so-called continuous-flow left ventricular assist devices (LVADs), in this case the Heartmate II LVAD (Thoratec Corp, Pleasanton, Calif), on end-organ function in patients with refractory heart failure awaiting a heart transplant. These pumps draw blood from the left ventricle via a drainage cannula placed in the LV apex on a continuous basis and propel the blood by a rotary pump back into the circulation in a nonphasic flow pattern2 through a return cannula connected to the aorta. The major findings of the Heartmate II clinical trial, including both the primary cohort2 and a larger number of patients enrolled in the continuous-access protocol,3 have previously been reported. Article see p 2352 This study examined the biochemical markers of hepatic and kidney function over a 6-month period after implantation of the Heartmate II LVAD in a cohort of 309 patients who were enrolled in the Heartmate II trial.2,3 These patients all had severe heart failure at the time of …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.